Biocon has commenced Phase I human clinical trials for IN105

Biocon has commenced Phase I human clinical trials of its oral insulin molecule, IN105 to establish Proof of concept of its proprietary oral delivery technology, recently acquired from Nobex. The studies are expected to be completed by Q3-FY07 and will be used to support IND filings with International Regulatory Authorities.

Source : Equity Bulls

Keywords